Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual Event

Jun 14, 2020 9:00 AM - Jun 18, 2020 5:00 PM

(Eastern Standard Time)

Horsham, PA 19044

DIA 2020 Global Annual Meeting

This event is now offered in a new entirely virtual format.

Leveraging Clinical Pharmacology to Transform Real World Data into Real World Evidence for Special Patient Populations

Session Chair(s)

Anuradha  Ramamoorthy, PharmD, PhD

Anuradha Ramamoorthy, PharmD, PhD

Policy Lead, OCP, OTS, CDER

FDA, United States

At the time of drug approval, information on optimal use of the drug may not be available for the entire range of patients who might need the drug. This includes certain ‘special populations’ who may be unstudied or understudied at the time of approval, for e.g., pediatrics, pregnant or lactating women, patients with compromised kidney or liver function, etc. This session will discuss opportunities for leveraging real-world data (RWD) to generate real-world evidence (RWE) to help personalize treatment for these special populations. The speakers will also highlight how clinical pharmacology-relevant (e.g., pharmacokinetic, pharmacodynamic, and pharmacogenomic) RWD can generate RWE to promote therapeutic individualization and supplement clinical trial and modelling and simulation data in special populations to make drug development and approval decisions. Case examples will be used to illustrate the key concepts.

Learning Objective : Describe the potential role for RWD and RWE in promoting therapeutic individualization in unstudied/understudied special patient subpopulations (e.g. pediatrics, compromised kidney/liver function); Discuss the opportunities and challenges in leveraging clinical pharmacology-relevant RWD to generate RWE.

Speaker(s)

Keith D. Wilner, PhD

Real World Evidence of Male Breast Cancer Patients Treated With Palbociclib in Combination With Endocrine Therapy: Extension of Indication

Keith D. Wilner, PhD

Pfizer Inc, United States

Executive Director, Oncology, Global Product Development

Frederick Joseph Derosier, DO

Leveraging Real World Data to Support the Development of Precision Medicines

Frederick Joseph Derosier, DO

Covance, United States

Executive Director, Rare Diseases

Pascal  Chanu, PharmD

Using Real World Data to Support Drug Development in Pediatric Patients: C.E.R.A. Case Study

Pascal Chanu, PharmD

Genentech, A Member of the Roche Group, France

Modeling and Simulation Expert

Qi  Liu, PhD

Use of Real World Data to Advance the Mission of Clinical Pharmacology

Qi Liu, PhD

FDA, United States

Assoc Director for Innovation and Partnerships, OCP, OTS, CDER

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.